157 related articles for article (PubMed ID: 33118519)
1. [Effect of ozone oil for prevention and treatment of sorafenib-induced hand-foot skin reactions: a randomized controlled trial].
Chen X; Jiang Y; Zhang Y; Dai W; Fan R; Weng X; He P; Yan F; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1488-1492. PubMed ID: 33118519
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
3. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
[TBL] [Abstract][Full Text] [Related]
4. Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.
Lien RY; Tung HH; Wu SL; Hu SH; Lu LC; Lu SF
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1532. PubMed ID: 34910380
[TBL] [Abstract][Full Text] [Related]
5. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
6. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
Wang P; Tan G; Zhu M; Li W; Zhai B; Sun X
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):1-8. PubMed ID: 28847184
[TBL] [Abstract][Full Text] [Related]
7. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
[TBL] [Abstract][Full Text] [Related]
8. β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma.
Naganuma A; Hoshino T; Ohno N; Ogawa Y; Murakami T; Horiguchi S; Uehara D; Suzuki Y; Hatanaka T; Kudo T; Ishihara H; Sato K; Kakizaki S; Takagi H
In Vivo; 2019; 33(1):155-161. PubMed ID: 30587616
[TBL] [Abstract][Full Text] [Related]
9. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
[TBL] [Abstract][Full Text] [Related]
10. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Lee JH; Chung YH; Kim JA; Shim JH; Lee D; Lee HC; Shin ES; Yoon JH; Kim BI; Bae SH; Koh KC; Park NH
Cancer; 2013 Jan; 119(1):136-42. PubMed ID: 22736425
[TBL] [Abstract][Full Text] [Related]
11. Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.
Ochi M; Kamoshida T; Ohkawara A; Ohkawara H; Kakinoki N; Hirai S; Yanaka A
World J Gastroenterol; 2018 Jul; 24(28):3155-3162. PubMed ID: 30065561
[TBL] [Abstract][Full Text] [Related]
12. Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?
Negri FV; Porta C
J Clin Oncol; 2015 Oct; 33(28):3219-20. PubMed ID: 26215963
[No Abstract] [Full Text] [Related]
13. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP; Franco PIG; Li RK
Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
[TBL] [Abstract][Full Text] [Related]
14. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
15. Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment.
Ochi M; Kamoshida T; Araki M; Ikegami T
World J Gastroenterol; 2021 Aug; 27(32):5424-5437. PubMed ID: 34539142
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management.
Ai L; Xu Z; Yang B; He Q; Luo P
Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1121-1127. PubMed ID: 31679411
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
18. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
Chang WT; Lu SN; Rau KM; Huang CS; Lee KT
Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012
[TBL] [Abstract][Full Text] [Related]
19. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
20. Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand-foot skin reactions in sorafenib-treated patients.
Saito K; Ikeda M; Kojima Y; Hosoi H; Saito Y; Kondo S
Cancer Chemother Pharmacol; 2018 Oct; 82(4):677-684. PubMed ID: 30062555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]